News
-
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
Telomir Pharmaceuticals announces promising findings from copper binding studies with Telomir-1, addressing Wilson's disease and metal toxicity. Telomir-1 shows potential in preclinical models for multiple conditions -
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Telomir Pharmaceuticals, Inc. raises $1 million in equity funding through The Starwood Trust, reinforcing financial strength. Telomir-1 shows transformative potential in addressing age-related conditions -
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1
Telomir Pharmaceuticals announces groundbreaking preclinical results showcasing Telomir-1's efficacy in reversing key parameters of Type 2 diabetes mellitus, potentially addressing insulin resistance at its root -
